AbbVie Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
AbbVie Stock Forecast and Price Target
AbbVie's stock is projected to advance by 14.78% from the previous closing price if it reaches the average target of $189.00 by the year's end, as eleven reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $206.00 and a low-end estimate of $161.00. Even if you are not interested in ABBV stock, it is still imperative to be aware of its competitors.
14.78% Upside
AbbVie Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, AbbVie's Price has seen a drop from $114.58 to $0.00 – a 100.00% decrease. For next year, the 18 analysts predict Fair Value of $130.09, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof $155.37, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£109.14 | Buy/Sell | £165.99 | 48.27% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.27 | Buy/Sell | $118.92 | 20.64% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$262.75 | Buy/Sell | $303.65 | 20.74% |
| ABI Stock Forecast | Anheuser-Busch InBev SA/NV | Outperform |
10
|
54.16€ | Buy/Sell | 69.40€ | 30.45% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.30 | Buy/Sell | $58.15 | 13.87% |
AbbVie Revenue Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's Revenue has grown, increasing from $45.80B to $54.32B – an increase of 18.59%. For next year, the 17 analysts predict Revenue of $56.47B, which would mean an increase of 3.97%. Over the next seven years, the pros' prediction is Revenueof $63.93B, which would mean a seven-year growth forecast of 17.69%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.84 | Buy/Sell | £17.30 | 23.11% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.15 | Buy/Sell | $284.47 | 20.09% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.54k | Buy/Sell | ¥5.24k | 27.87% |
.jpg)
AbbVie Dividend per Share Forecast for 2023 - 2025 - 2030
AbbVie's Dividend per Share has increased by 23.76% In the last three years, going from $4.84 to $5.99. In the next year, analysts expect Dividend per Share to reach $6.17 – an increase of 3.01%. For the next seven years, the forecast is for Dividend per Share to grow by 2.34%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.09k | Buy/Sell | ¥4.92k | 20.83% |
| MMM Stock Forecast | 3M | Hold |
10
|
$91.48 | Buy/Sell | $109.39 | 9.31% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF72.12 | Buy/Sell | CHF90.64 | 33.61% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
135.60€ | Buy/Sell | 137.41€ | 9.88% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$190.52 | Buy/Sell | $299.62 | 53.26% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.24€ | Buy/Sell | 45.15€ | 21.95% |
AbbVie EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's EBITDA has grown by 18.89%, from $22.17B to $26.36B. For the next year, analysts are expecting EBITDA to reach $27.42B – an increase of 4.02%. Over the next seven years, experts predict that EBITDA will grow by 20.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr1.99k | Buy/Sell | kr2.71k | 28.60% |
| 4452 Stock Forecast | Kao | Outperform |
18
|
¥6.18k | Buy/Sell | ¥5.95k | 4.21% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$90.07 | Buy/Sell | $111.56 | 20.68% |
AbbVie EBIT Forecast for 2023 - 2025 - 2030
In the last three years, AbbVie's EBIT has grown from $15.70B to $17.66B – a 12.49% increase. Next year, analysts are expecting EBIT to reach $26.64B – an increase of 50.85%. Over the next seven years, the forecast is for EBIT to grow by 77.73%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BGNE Stock Forecast | BeiGene | Buy |
6
|
$131.96 | Buy/Sell | $285.19 | 108.40% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp5.96k | Buy/Sell | Rp5.67k | 1.53% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.82 | Buy/Sell | $77.05 | 46.16% |
AbbVie EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, AbbVie's EPS has seen a drop from $10.56 to $0.00 – a 100.00% decrease. For next year, the 18 analysts predict EPS of $11.99, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof $14.32, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥5.82k | Buy/Sell | ¥9.58k | 44.23% |
| BBWI Stock Forecast | Bath & Body Works | Outperform |
15
|
$43.86 | Buy/Sell | $45.28 | 18.56% |
| COTY Stock Forecast | Coty Inc | Outperform |
16
|
$11.04 | Buy/Sell | $13.33 | 17.75% |
.jpg)